Breaking News Instant updates and real-time market news.

MRK

Merck

$60.24

1.42 (2.41%)

16:34
04/23/18
04/23
16:34
04/23/18
16:34

Merck: Centralized review process has started for Type II Variation for Keytruda

Merck announced that following validation by the European Medicines Agency, the centralized review process has begun for the company's Type II Variation, which seeks approval for KEYTRUDA, Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer. The application was accepted for review based on overall survival and progression-free survival data from the Phase 3 KEYNOTE-189 trial, which were recently presented at the American Association of Cancer Research 2018 Annual Meeting and published simultaneously in The New England Journal of Medicine. If approved by the EMA, this would mark the third indication for KEYTRUDA in metastatic NSCLC to be approved in Europe based on overall survival data.

  • 23

    Apr

  • 24

    Apr

  • 27

    Apr

  • 01

    May

  • 08

    May

  • 05

    Jun

  • 23

    Oct

MRK Merck
$60.24

1.42 (2.41%)

04/17/18
04/17/18
UPGRADE
Target $68

Overweight
Merck upgraded to Overweight on immuno-oncology leadership at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Merck (MRK) to Overweight from Equal Weight after the Keytruda+chemo combination showed better than expected results in lung cancer, boosting the company's immuno-oncology lead against Bristol-Myers (BMY). Driven by higher Keytruda estimates, Risinger increased his 2018-23 EPS CAGR estimate to 8% from 6% and raised his out-year EPS forecasts by 5-8%. The analyst, who also downgraded Bristol-Myers to Equal Weight from Overweight this morning, raised his price target on Merck shares to $68 from $63.
04/17/18
04/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Hold from Sell at Pivotal Research with analyst Brian Wieser saying the company "has a lot of positive elements" heading into the back half of the year, including a strong film slate, the launch of new direct to consumer over-the-top services, and efforts in support of the close of the Fox (FOXA) transaction. 2. Coca-Cola (KO) upgraded to Neutral from Sell at Goldman Sachs with analyst Judy Hong saying she sees an improving organic sales growth outlook, "cleaner base" post-refranchising, and better visibility on its margin and earnings targets. 3. Merck (MRK) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying the Keytruda+chemo combination showed better than expected results in lung cancer, boosting the company's immuno-oncology lead against Bristol-Myers (BMY). 4. Newell Brands (NWL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog saying the stock's setup is good looking forward, with greater potential upside than downside risk over the next 12 months. 5. Twitter (TWTR) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Brian Nowak citing recent advertiser conversations that have continued to be incrementally positive about Twitter's ad business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/18
GSCO
04/23/18
UPGRADE
GSCO
Conviction Buy
Merck upgraded to Conviction Buy from Neutral at Goldman Sachs
04/23/18
GSCO
04/23/18
UPGRADE
Target $73
GSCO
Conviction Buy
Goldman upgrades Merck to Buy, puts on Conviction List with $73 target
Goldman Sachs analyst Jami Rubin upgraded Merck to Buy from Neutral and added the shares to her firm's Conviction List. Rubin also upped her price target for the shares to $73 from $63. Merck closed Friday up 20c to $58.83. The analyst increased her estimates for Keytruda sales by $2B in 2021 and $4B in 2025. The narrative for Merck is "quickly changing with the success of Keytruda, driving a significant shift in product mix from a large primary care evolving into a specialty biopharma," Rubin tells investors in a research note. The analyst now sees "significant" margin upside from product mix shift with higher Keytruda sales than previously modeled. She believes Merck's operating margins could go from 32.5% in 2017 to 40% by 2025, with an inflection point beginning in the second half of 2018.

TODAY'S FREE FLY STORIES

TNXP

Tonix Pharmaceuticals

$4.62

0.04 (0.87%)

14:27
06/19/18
06/19
14:27
06/19/18
14:27
Hot Stocks
Breaking Hot Stocks news story on Tonix Pharmaceuticals »

Regals Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$51.97

0.04 (0.08%)

14:25
06/19/18
06/19
14:25
06/19/18
14:25
Options
Lennar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FB

Facebook

$196.88

-1.42 (-0.72%)

14:25
06/19/18
06/19
14:25
06/19/18
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a follow-up hearing »

The Subcommittee on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

ES

Eversource

$55.59

0.505 (0.92%)

, CTWS

Connecticut Water

$66.09

0.34 (0.52%)

14:23
06/19/18
06/19
14:23
06/19/18
14:23
Hot Stocks
Eversource reiterates Connecticut Water proposal, urges holders vote against SJW »

Eversource Energy (ES)…

ES

Eversource

$55.59

0.505 (0.92%)

CTWS

Connecticut Water

$66.09

0.34 (0.52%)

SJW

SJW Corp.

$67.82

1.31 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/19/18
06/19
14:17
06/19/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$146.84

-3.69 (-2.45%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Hot Stocks
Whirlpool drops further after AHAM data released »

Shares of Whirlpool have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/19/18
06/19
14:16
06/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYDY

CytoDyn

$0.00

(0.00%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities Association »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ZS

Zscaler

$37.56

-2.8 (-6.94%)

14:15
06/19/18
06/19
14:15
06/19/18
14:15
Options
Zscaler Inc put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

YPF

YPF

$16.57

0.35 (2.16%)

14:05
06/19/18
06/19
14:05
06/19/18
14:05
Options
YPF call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$67.79

-1.96 (-2.81%)

13:55
06/19/18
06/19
13:55
06/19/18
13:55
Options
Xilinx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.19

-0.215 (-0.73%)

13:49
06/19/18
06/19
13:49
06/19/18
13:49
Hot Stocks
Merrill Lynch to pay $42M penalty to settle SEC charges on trade 'masking' »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.54

-2.76 (-1.39%)

13:47
06/19/18
06/19
13:47
06/19/18
13:47
Hot Stocks
Facebook takes steps to make video more interactive »

Facebook shares updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

COTV

Cotiviti Holdings

$44.00

4.105 (10.29%)

13:43
06/19/18
06/19
13:43
06/19/18
13:43
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$140.20

34.72 (32.92%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

COTV

Cotiviti Holdings

$44.03

4.14 (10.38%)

13:41
06/19/18
06/19
13:41
06/19/18
13:41
Downgrade
Cotiviti Holdings rating change  »

Cotiviti Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/19/18
06/19
13:40
06/19/18
13:40
Options
Alerian MLP attracts a large put buyer »

Alerian MLP attracts a…

FMBH

First Mid-Illinois Bancshares

$41.10

0.25 (0.61%)

13:39
06/19/18
06/19
13:39
06/19/18
13:39
Conference/Events
First Mid-Illinois Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 24

    Sep

STE

STERIS

$106.73

-0.82 (-0.76%)

13:37
06/19/18
06/19
13:37
06/19/18
13:37
Conference/Events
STERIS management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SRPT

Sarepta

$143.85

38.37 (36.38%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAIN

Hain Celestial

$29.55

0.69 (2.39%)

13:35
06/19/18
06/19
13:35
06/19/18
13:35
Options
Hain Celestial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.38

0.175 (0.54%)

, VZ

Verizon

$48.54

1.08 (2.28%)

13:34
06/19/18
06/19
13:34
06/19/18
13:34
Periodicals
AT&T to end sale of user location data to third-party brokers, Verge reports »

AT&T (T) plans to end…

T

AT&T

$32.38

0.175 (0.54%)

VZ

Verizon

$48.54

1.08 (2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

ORCL

Oracle

$46.18

-0.36 (-0.77%)

, MSFT

Microsoft

$100.35

-0.53 (-0.53%)

13:23
06/19/18
06/19
13:23
06/19/18
13:23
Earnings
On The Fly: What to watch for in Oracle's earnings report »

Oracle (ORCL) is…

ORCL

Oracle

$46.18

-0.36 (-0.77%)

MSFT

Microsoft

$100.35

-0.53 (-0.53%)

IBM

IBM

$143.49

-0.96 (-0.66%)

HPE

HP Enterprise

$15.78

-0.14 (-0.88%)

AMZN

Amazon.com

$1,712.48

-11.58 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 10

    Jul

XLU

Utilities SPDR

$49.96

0.27 (0.54%)

13:20
06/19/18
06/19
13:20
06/19/18
13:20
Options
SPDR Repeat put buying in SPDR Utility ETF as the sector sees relative strength »

SPDR Repeat put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
06/19/18
06/19
13:20
06/19/18
13:20
General news
Treasury Action: so far there's no sign of a general boycott on Treasuries »

Treasury Action: so far…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.